In:
Pathobiology, S. Karger AG, Vol. 90, No. 4 ( 2023), p. 219-232
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 To evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 GATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92–99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage ( 〈 i 〉 p 〈 /i 〉 = 0.03), high BRE grade ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.0001), HER2 overexpression ( 〈 i 〉 p 〈 /i 〉 = 0.0085), estrogen and progesterone receptor negativity ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.0001 each), and reduced survival ( 〈 i 〉 p 〈 /i 〉 = 0.03). 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Our data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.
Type of Medium:
Online Resource
ISSN:
1015-2008
,
1423-0291
Language:
English
Publisher:
S. Karger AG
Publication Date:
2023
detail.hit.zdb_id:
1483541-1
SSG:
12
Bookmarklink